Off-label Use of Medications, Biologics, and Devices in Orthopaedic Trauma Creates a Bevy of Risks and Challenges

Arun Aneja, MD, PhD; Jonathan Grabau, MD

Following FDA approval, any marketing or promotion of a given medications, biologics, and devices (MBD) is strictly restricted to the approved indication. Discretion on how to use devices on the market for patients is the responsibility of clinicians.

AAOS Accepting Submissions for 2022 Kappa Delta and OREF Awards

AAOS is soliciting manuscripts for the 2022 Kappa Delta Orthopaedic Research Awards and the Orthopaedic Research and Education Foundation (OREF) Clinical Research Award.

Peter S. Rose, MD, Will Be the Next Editor-in-Chief of JAAOS ®

Kerri Fitzgerald

Peter S. Rose, MD, FAAOS, professor of orthopaedic surgery and division chair of orthopaedic oncology at Mayo Clinic in Rochester, Minn., has been named the next editor-in-chief of the Journal of the AAOS (JAAOS) ®.